Published on 26 Dec 2023 on Zacks via Yahoo Finance

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

Senti Biosciences, Inc. SNTI announced that the FDA has cleared its investigational new drug (IND) application to begin clinical studies on its chimeric antigen receptor natural killer (CAR-NK) cell therapy candidate, SENTI-202, for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). Shares of the company were up 18.7% on Dec 22, following the announcement of the news.

Per management, a potential first-in-class off-the-shelf CAR-NK cell therapy, SENTI-202, is being developed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, like AML and myelodysplastic syndrome (MDS), while not affecting the healthy bone marrow cells.

Following the FDA’s clearance of the IND, Senti Bio plans to initiate a phase I study on SENTI-202 at various sites in the United States and Australia. The first patient in the study is expected to be treated in the second quarter of 2024.